Original Article
Clinical Investigation

Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment

Makito Miyake,1 Eiji Kikuchi,2 Kenta Shinozaki,3 Yi Piao,3 Nobuya Hayashi,3 Ryo Koto,3 Masahisa Jinushi3 and Takashi Kobayashi4

1Department of Urology, Nara Medical University, Nara, 2Department of Urology, St. Marianna University School of Medicine, Kanagawa, 3AstraZeneca K.K., Osaka, and 4Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Objectives: To investigate current patterns and outcomes of intravesical bacillus Calmette-Guérin treatment in Japanese patients with bladder cancer, including the proportion of patients completing induction therapy, and time to subsequent treatments.

Methods: This retrospective cohort study utilized administrative claims data from the Medical Data Vision Co., Ltd. database to identify patients with a diagnosis of bladder cancer who had received ≥1 prescription of intravesical bacillus Calmette-Guérin between April 2008 and September 2015, and had ≥1 database record dated ≥12 weeks after the initial bacillus Calmette-Guérin dose. Patients were followed until September 2018, the last date of available data, or in-hospital death. Patients receiving six doses of bacillus Calmette-Guérin at intervals of <21 days were considered to have completed induction according to guidelines. Time from initial bacillus Calmette-Guérin dose to subsequent bladder cancer treatment after the end of treatment was defined as the recurrence-free duration.

Results: Of 6140 patients identified (median age 73.0 years; 83.4% males), 4588 (74.7%) completed induction and 1552 (25.3%) did not. Median recurrence-free duration was 64.4, 77.7, and 31.6 months in the overall, complete-induction and incomplete-induction cohorts, respectively. Corresponding 3-year recurrence-free rate was 56.3%, 59.0%, and 48.2% in these groups. The rate of cystectomy was approximately 6% at 5 years in all cohorts.

Conclusions: Approximately 75% of Japanese patients who undergo intravesical bacillus Calmette-Guérin treatment receive a guideline-compliant induction regimen, but outcomes were not satisfactory, highlighting the need for more effective treatments for non-muscle invasive bladder cancer.

Key words: BCG vaccine, humans, Japan, treatment outcome, urinary bladder neoplasms.

INTRODUCTION

Bladder cancer is the tenth most common cancer in the world,1 and its incidence is projected to increase by 73% over the next 20 years.2 Japanese men have the highest age-standardized incidence of bladder cancer in Central and Eastern Asia, with 9.6 cases per 100 000 diagnosed annually.3

Approximately 70–75% of newly diagnosed bladder cancers are classified as NMIBC.4–6 NMIBC can be treated with TURBT, followed by adjuvant intravesical instillation of BCG or chemotherapy. The recommended therapy is induction and maintenance therapy with intravesical BCG for intermediate- and/or high-risk patients.4–7 Intravesical BCG has been used for over 30 years to treat bladder cancer,8 and demonstrated to reduce the risk of recurrence and progression after TURBT.9,10

The US and European guidelines recommend six once-weekly intravesical instillations of BCG.4,6 Although there is strong evidence to support the use of BCG for treating NMIBC, there is limited evidence to support any one regimen for BCG induction,11 and there are currently limited real-world data on how BCG is administered, or what the outcomes are, during...
routine clinical practice in Japan. It is assumed that in the real-world setting, various patterns of intravesical BCG treatment (including patterns not adhering to the guidelines) would be applied to patients with high-risk NMIBC.

This study (the ‘KEGON’ study) aimed to investigate the current patterns and outcomes of intravesical BCG treatment in Japanese patients with bladder cancer, including the extent to which these adhere to guidelines, and the characteristics of patients receiving this treatment, the proportion of patients completing induction therapy with or without receiving maintenance therapy, and the treatments they received after intravesical BCG treatment has failed.

METHODS

Study design

This was a retrospective cohort study using secondary data from the MDV (Tokyo, Japan) anonymized administrative claims database, which includes hospital-based claims data and Diagnosis Procedure Combination/per diem payment system data. We identified patients who had a diagnosis of bladder cancer (ICD10 code: C67x), received ≥1 prescription of intravesical BCG between April 2008 and September 2015, and had ≥1 medical record in the database dated ≥12 weeks after initial intravesical BCG. Patients were followed until September 2018, the last date of available data, or in-hospital death, whichever came first. This study was reviewed and approved by an independent ethics committee (Non-Profit Organization MINS Institutional Review Board, Approval ID: 200217).

The index date (Day 1) was defined as the date of the initial prescription of intravesical BCG. The BCG induction period was from the index date until Day 84 (12 weeks), and the first intravesical BCG treatment period was defined as the time from the index date to the last BCG prescription (Fig. S1).

This study included two cohorts and two sub-cohorts as follows (Fig. S2): (i) the complete-induction cohort included patients who received ≥6 BCG prescriptions, had intervals of ≥21 days between consecutive BCG prescriptions during the initial six prescriptions, and had no other treatment during the BCG induction period; (ii) the incomplete-induction cohort included patients who did not meet the criteria for the complete-induction cohort and whose treatment did not adhere to guidelines; (iii) the intensive-induction subcohort included patients who met the criteria for the complete-induction cohort and had intervals of <8 days between consecutive BCG prescriptions during the BCG induction period; and (iv) the non-intensive-induction subcohort included patients who met the criteria for the complete-induction cohort but did not meet the criteria for the intensive-induction cohort.

According to the Japanese guideline, standard regimen is 6–8 doses of weekly intravesical BCG treatment, called “BCG induction therapy,” followed by regular intravesical BCG treatment, called “BCG maintenance therapy.” The intensive induction subcohort was defined as the guideline-adherent group, and the incomplete induction and non-intensive induction subcohorts as the nonadherent group.

Endpoints

First, we described the treatment pattern of intravesical BCG and the baseline characteristics of patients in each cohort at the index date, including relevant comorbidities (renal/urinary tract cancers other than bladder cancer, genitourinary symptoms, benign prostatic hyperplasia, and autoimmune diseases). Table S1 describes how these data were derived from the database entries.

Other endpoints included the time from the index date to the beginning of the subsequent treatment for bladder cancer, which was assumed to be the date of recurrence; this parameter was therefore an estimate of recurrence-free duration. Table S2 provides definitions of subsequent treatments. Other secondary endpoints were the time from the index date to the date of cystectomy (cystectomy-free duration), and the subsequent treatment patterns for bladder cancer after the first intravesical BCG treatment in the total population and each cohort. The number of intravesical BCG prescriptions within the BCG induction period (from Day 1 to 84) was also assessed as an exploratory outcome.

Statistical analysis

Continuous variables (e.g., age, duration) were summarized using means, SD, medians, minimums, maximums, and IQR as appropriate. Frequency and percentages were used to summarize categorical variables. The Kaplan–Meier method was used to assess the time to any events and to estimate median and its 95% CIs. HRs with 95% CIs between complete and incomplete inductions were estimated based on a proportional hazards model. Recurrence-free duration and cystectomy-free duration were calculated based on the time from the index date to the occurrence of the subsequent treatment for bladder cancer and cystectomy, respectively. All analyses were performed using SAS® Version 9.4 (SAS Institute Inc., Cary, NC, USA).

As this was a database study, the target population included patients for whom intravesical BCG was not indicated (e.g., patients with stage ≥II disease), and subsequent TURBT could be performed with diagnostic intent (rather than therapeutic), or as biopsy for suspicious lesions during the follow-up. Therefore, sensitivity analysis was performed to examine outcomes in more limited patient populations: (i) only those patients with stage 0 or I disease at baseline; and (ii) excluding TURBT from the subsequent treatment. We also performed a sensitivity analysis in which the intensive and non-intensive cohorts were defined by an interval of <9 or ≥9 days, respectively, between consecutive intravesical BCG prescriptions during induction to reflect the brief postponements typically encountered in clinical practice as a result of weekends and public holidays.

RESULTS

Patient selection in the database and BCG treatment pattern

The MDV database included data for 63 910 patients with bladder cancer between April 2008 and September 2015. Of
these patients, 6140 (9.6%) met the study inclusion criteria and comprised the overall study cohort (Fig. 1); 4588 (74.7%) comprised the complete-induction cohort and 1552 (25.3%) the incomplete-induction cohort.

**Patient characteristics**

In the overall cohort, most patients (83.4%) were male and almost two-thirds were aged ≥70 years (63.6%; Table 1). Among 3839 patients with cancer stage data, most had stage 0 or I disease (39.2% and 52.3%, respectively), and 8.5% had stage ≥II. The most common of the comorbidities investigated were genitourinary signs and symptoms (47.3% of patients), benign prostatic hyperplasia (40.6% of men), and cancer other than bladder cancer (26.5%). Overall, 4.9% and 8.1% of patients had malignant neoplasms of the renal pelvis or ureter, respectively, in addition to bladder cancer.

Demographic and clinical characteristics of the complete-induction cohort and the incomplete-induction cohort are summarized in Table 1.

**Intravesical BCG and subsequent treatment**

In the overall patient group, patients received between 1 and 10 prescriptions of intravesical BCG. The median (IQR) number of prescriptions was 7.0 (6.0–8.0) in the overall group, 4.0 (3.0–6.0) in the incomplete-induction cohort, and 8.0 (6.0–8.0) in the complete-induction cohort (Table 2). The median (IQR) duration of follow-up was 45.5 (35.7–59.3) months or approximately 3.74 years.

The most common subsequent treatment after intravesical BCG was TURBT; 44.5% of patients received TURBT only, and another 20.0% of patients received TURBT and a second course of intravesical BCG (Fig. 2). All other treatments or combinations were used in <10% of patients.

**Time to subsequent treatment**

The median duration from the index date to subsequent treatment for bladder cancer was 64.4 months (95% CI 55.2–72.7) in the overall cohort (Fig. 3a), 77.7 months (95% CI 66.2–91.4) in the complete-induction cohort, and 31.6 months (95% CI 25.6–39.3) in the incomplete-induction cohort (Fig. 3b).

The 6-month, 1-year, and 5-year recurrence-free rates were 81.8%, 70.4%, and 50.7%, respectively, in the overall cohort. Complete induction was associated with an increase of ~50% in the duration from initial intravesical BCG treatment to subsequent treatment compared with incomplete induction (HR 1.46; 95% CI 1.35–1.59). However, the difference was most marked in the first 3 months; thereafter, the curves were almost parallel (Fig. 3b).

Immortal time bias may impact results since patients in the complete-induction cohort did not have early recurrence (which would have interrupted their induction treatment), whereas the patients in the incomplete cohort may have had early recurrence. The clinical characteristics of the patients with (n = 248) and without (n = 1304) early (Day 1–84) events in the incomplete-induction cohort are provided in Table S3.

The cystectomy rate after the initial intravesical BCG treatment was low in both the complete- and incomplete-induction cohorts (5.5% and 6.3% at 5 years, respectively). As a result, median duration from the index date until cystectomy was not reached in any cohort (Fig. 4a,b).
The results of the sensitivity analyses were consistent with original analyses (Figs S3–S5).

**Intensive induction BCG versus non-intensive induction BCG**

Among patients in the complete-induction cohort, 2105 (45.9%) received intensive induction therapy with an interval of <8 days between consecutive intravesical BCG treatment, and 2483 (54.1%) received non-intensive induction. In the latter cohort, the mode of the interval between intravesical BCG administrations was 7 days, but the maximum interval ranged from 8 to 46 days (mode of the maximum interval was 14 days). Demographic and clinical characteristics in these two cohorts are shown in Table 3.

The 6-month, 1-year, and 5-year recurrence-free rates were 84.8%, 71.8%, and 51.8%, respectively, in the intensive-induction cohort and 84.7%, 74.4%, and 54.2%, respectively, in the non-intensive-induction cohort (Fig. 5a). The recurrence-free curves (Fig. 5a) and the cystectomy-free curves (Fig. 5b) of the two cohorts overlapped.

The results of sensitivity analyses examining the impact of a <9-day interval between intravesical BCG prescriptions were similar to the original analyses (Figs S6, S7; Table S4).

**DISCUSSION**

This retrospective observational study indicates that about 75% of Japanese patients treated with intravesical BCG for bladder cancer received ≥6 intravesical doses with an interval of <21 days between consecutive doses, which we defined as complete induction therapy or “guideline-adherent” induction therapy.

While selection bias is inherent in any retrospective database analysis, which is dependent on the quantity and quality of the data in the database, the characteristics of patients in our study can be compared with those in the previous JUA registry of patients with NMIBC (n = 3237). As in the JUA registry, the proportion of women with bladder cancer was <20% in our study, and our cohort included a high proportion of patients older than 70 years (63.6% vs 48.7% in the JUA registry). It should be noted that, unlike the JUA registry, our cohort was not limited to treatment-naïve patients with NMIBC, which may explain our higher proportion of older patients. Based on the broad coverage of the MDV database (it is estimated that 41% of Japanese bladder cancer cases might be covered in the database), we assume that our results are generalizable to a high proportion of the Japanese population.
A 2015 consensus paper noted that no regimen has proven to be significantly more effective than the original schedule of six once-weekly intravesical BCG injections reported by Morales et al. in 1976. Intravesical BCG maintenance therapy is also recommended in the guidelines; however, no standardized regimen of BCG maintenance therapy has been
established, which made it difficult to accurately capture patients who received BCG maintenance therapy from the database. Therefore, we focused on intravesical BCG induction therapy in this study.

To our knowledge, this is the first study to investigate patient characteristics and outcomes in patients who completed induction therapy as described in the guidelines with those who did not complete induction, and we found that demographic and clinical characteristics were generally numerically consistent between the two cohorts.

One-year recurrence rates were around 30% in the overall population and complete-induction cohort. Patients who did not complete induction therapy were at higher risk of recurrence, especially early recurrence, whereas their characteristics as determined from the database were numerically consistent with those of the complete-induction cohort. Prior research has shown that complete response to induction BCG therapy is associated with a lower rate of recurrence. In our study, it was not possible to determine the response to induction therapy.

The 5-year recurrence-free rate in our study (50.7% overall and 53.1% in those who completed induction) is a little higher than the 47.0% rate reported by Malmström and colleagues in their comparison of BCG induction followed by maintenance with mitomycin C treatment. However, the 5-year recurrence-free rates are lower in our study than studies by Martínez-Piñeiro et al., in which the rate was 62–67%, and by Farah et al., in which it was 69%. These differences likely reflect a number of factors including use and duration of maintenance therapy after induction, different BCG strains, and the intensity of follow-up in clinical trials compared with routine clinical practice.

The rate of cystectomy after intravesical BCG treatment was low in our study (only approximately 6% after 5 years) and was unaffected by completion of induction therapy or by the intensity of induction therapy. The current guidelines

---

**FIGURE 4** Kaplan–Meier curves of time from first intravesical BCG prescription to cystectomy in the (a) overall cohort, and (b) complete- and incomplete-induction cohorts.
recommend that cystectomy should be considered for patients with BCG-unresponsive disease, according to established definitions.18-21 While we were unable to identify the patterns of intravesical BCG failure (i.e., BCG unresponsiveness, BCG relapse and BCG intolerance), cystectomy was not widely performed after BCG failure in real-world Japanese practice. In fact, the rate was lower than in a report from the US, which indicated that 29% of patients had immediate cystectomy after diagnosis of BCG-unresponsive recurrence.21 Because cystectomy was so rarely performed in the current cohort of Japanese patients, our study was underpowered to detect differences in cystectomy rates between patient cohorts.

The effectiveness of intravesical BCG in NMIBC is thought to be mediated by activation of the innate immune system.8 Innate immunity plays an important role in the development of acquired T-cell immunity in which immune checkpoint inhibitors (including programmed cell death protein-1 and programmed death ligand-1) are involved. Intravesical BCG would help effective development of T-cell immunity and have synergy when used in combination with immuno-oncology agents.

Since bladder cancer is an immunogenic tumor, studies are now underway to investigate the use of immune checkpoint inhibitors such as durvalumab and pembrolizumab instead of, or in combination with BCG, in patients with BCG-naive high-risk NMIBC, and as treatment in patients with BCG-unresponsive NMIBC (Table 4). In order to interpret the evidence from these clinical trials, it is necessary to establish the extent to which the comparator BCG regimens reflect current clinical use of intravesical BCG for NMIBC in the real world. Data from the current study will meet this need for Japan.

Because this study used the MDV database, there are several limitations. First, the database does not merge data from an individual patient receiving treatment at more than one hospital, so if a patient had received any treatment for bladder cancer at another hospital, these data would not be identified. Therefore, patients who transferred to other healthcare facilities during the course of their treatment were lost to follow-up. Second, the MDV database does not record deaths that occur outside hospital; therefore we were not able to evaluate survival in this study. Third, the first BCG prescription captured in the database might not be the first one for the patient, and subsequent treatments might not be fully captured. As a result, the recurrence-free duration rate might be overestimated. Furthermore, the database does not provide information on the indication for BCG. As such, we were not able to identify patients for whom BCG was used to treat carcinoma in situ, or those who received BCG as maintenance therapy. Since maintenance use of BCG is recognized as having an influence on tumor recurrence, this may have affected our results, particularly in the complete-induction cohort. Similarly, we were not able to differentiate between TURBT use for diagnosis or for treatment. Future prospective studies are expected to address these by collecting all relevant clinical information for more comprehensive analysis. Finally, the database included data for all patients, irrespective of whether they were treated according to guidelines; this explains why our analysis included some patients with stage II–IV disease because this would have contravened the study objective of describing the real-world use of BCG in patients with bladder cancer.

In conclusion, in Japan, 74.7% of bladder cancer patients who start induction treatment with intravesical BCG completed it. Completion of such treatment is associated with less recurrence; thus, completion is important even if the intervals between each dose are prolonged due to adverse events. Approximately 30% of patients need subsequent treatment within a year of starting intravesical BCG treatment for NIMBC, and 44% need subsequent treatment within 3 years, indicating that more effective treatments are needed for NIMBC.

**ACKNOWLEDGMENTS**

We thank Catherine Rees of inScience Communications, Springer Healthcare, who provided writing and editorial services.

---

### Table 3: Demographic and clinical characteristics, and BCG induction treatment pattern, of the overall patient cohort, complete-induction cohort, and intensive- and non-intensive-induction cohorts

| Age, years | Mean (SD) | Median | Non-intensive-induction cohort (n = 2483) | Intensive-induction cohort (n = 2105) | Complete-induction cohort (n = 4588) |
|------------|-----------|--------|----------------------------------------|--------------------------------------|-------------------------------------|
| <0 years   | 102.1 (1.7)| 77.1 (1.7) | 33 (1.6) | 44 (1.8) | 72.4 (9.6) |
| 0–20 years | 452.7 (7.4)| 358 (7.8)| 147 (7.0) | 211 (8.5) | 72.1 (9.5) |
| 21–30 years| 1683.2 (27.4)| 1303 (28.4)| 625 (29.7) | 678 (27.3) | 72.1 (9.4) |
| 31–40 years| 2375.3 (38.7)| 1763 (38.4)| 795 (37.8) | 968 (39.0) | 72.0 (9.6) |
| 41–50 years| 1349.4 (23.4)| 1031 (22.5)| 481 (22.9) | 550 (22.2) | 73.0 |
| >50 years  | 89.1 (1.4) | 56 (1.2)| 24 (1.1) | 32 (1.3) | 73.0 |

---

**TABLE 3** Demographic and clinical characteristics, and BCG induction treatment pattern, of the overall patient cohort, complete-induction cohort, and intensive- and non-intensive-induction cohorts.
assistance for the outline and manuscript drafts. We would also like to thank EPS Corporation for performing the data analyses for this study. This medical writing assistance and analyses were funded by AstraZeneca K.K.

**AUTHOR CONTRIBUTIONS**

Makito Miyake: Conceptualization; methodology; writing – review and editing. Eiji Kikuchi: Conceptualization; methodology; writing – review and editing. Kenta Shinozaki: Conceptualization; methodology; writing – original draft; writing – review and editing. Yi Piao: Data curation; methodology; writing – review and editing. Nobuya Hayashi: Formal analysis; methodology; writing – review and editing. Ryo Koto: Data curation; methodology; writing – review and editing. Masahisa Jinushi: Conceptualization; funding acquisition; methodology; writing – review and editing. Takashi Kobayashi: Conceptualization; methodology; writing – review and editing.

**CONFLICT OF INTEREST**

EK has received honoraria from NIPPON KAYAKU and AstraZeneca K.K. KS, YP, NH, RK, and MJ are employees of AstraZeneca K.K. and hold stocks of AstraZeneca PLC. MJ was an employee of AstraZeneca K.K. at the time this analysis was conducted. TK has received research support from AstraZeneca K.K.

**APPROVAL OF THE RESEARCH PROTOCOL BY AN INSTITUTIONAL REVIEWER BOARD**

This study was reviewed and approved by an independent ethics committee (Non-profit Organization MINS Institutional Review Board, Approval ID: 200217).

**INFORMED CONSENT**

N/A.
TABLE 4  Studies underway that investigate the use of immune checkpoint inhibitors in patients with NMIBC

| NCT number (study name) | Target N | Phase | Patients | Treatment groups | Primary endpoint | Estimated date of completion |
|-------------------------|----------|-------|----------|------------------|-----------------|-----------------------------|
| Avelumab                |          |       |          |                  |                 |                             |
| NCT03892642             | 27       | 1/2   | BCG-unresponsive | Avelumab + BCG | Proportion of patients completing induction course | October 2025 |
| NCT03950362 (PREVERT)  | 67       | 2     | BCG-unresponsive | Avelumab + radiotherapy | High-risk recurrence-free survival | June 2024 |
| Durvalumab              |          |       |          |                  |                 |                             |
| NCT03258593             | 40       | 1     | BCG-unresponsive | Durvalumab induction ± maintenance with vicinium induction and maintenance | Safety and tolerability | December 2022 |
| NCT02901548             | 17       | 2     | BCG-unresponsive | Durvalumab | 6-month complete response rate | December 2021 |
| NCT03759496             | 39       | 2     | BCG-unresponsive | Durvalumab | Maximum tolerated dose Possibility of rate of high-grade relapse-free after start of durvalumab 1-year high-grade relapse-free rate | December 2021 |
| Pembrolizumab           |          |       |          |                  |                 |                             |
| NCT03317158 (ADAPT-BLADDER) | 186    | 1/2   | BCG-unresponsive | Durvalumab monotherapy (phase 1) Durvalumab + BCG (phase 2) Durvalumab + radiotherapy (phase 2) | Recommended dose (phase 1) 6-month relapse-free survival (phase 2) | March 2023 |
| NCT04106115             | 64       | 1b/2  | BCG-unresponsive | Durvalumab + 5-peptide cancer vaccine (S-488210/5-488211) | Dose-limiting toxicity (phase 1) 1-year disease-free survival (phase 2) | July 2027 |
| NCT03528694 (POTOMAC)  | 1018     | 3     | BCG-naive | Durvalumab + BCG induction and maintenance Durvalumab + BCG induction only Durvalumab induction and maintenance | Disease-free survival | November 2024 |
| Pembrolizumab           |          |       |          |                  |                 |                             |
| NCT02808143             | 9        | 1     | BCG-unresponsive | Pembrolizumab preinduction then BCG induction and maintenance Pembrolizumab induction + BCG induction | Maximum tolerated dose | February 2022 |
| NCT02324582             | 13       | 1     | BCG-unresponsive | Pembrolizumab induction + BCG induction | Safety | December 2022 |
| NCT03504163             | 37       | 2     | BCG-naive | Pembrolizumab | 6-month disease-free rate | April 2022 |
| NCT04387461             | 37       | 2     | BCG-unresponsive | Pembrolizumab + CG0070 | Complete response rate | June 2022 |
| NCT04164082             | 161      | 2     | BCG-unresponsive | Pembrolizumab + gemcitabine | 6-month complete response rate 18-month event-free survival | March 2023 |
| NCT02625961 (KEYNOTE-057) | 260    | 2     | BCG-unresponsive | Pembrolizumab | Complete response rate | July 2023 |
| Pembrolizumab           |          |       |          |                  | Disease-free survival rate |                             |
| NCT03711032 (KEYNOTE-676) | 1525  | 3     | BCG-naive or BCG-unresponsive NMIBC | BCG induction and pembrolizumab + BCG maintenance (full or reduced maintenance regimen in BCG-naive cohort) BCG induction and maintenance | Complete response rate Event-free survival | November 2024 |
| Sasanlimab              |          |       |          |                  |                 |                             |
| NCT04165317 (CREST)     | 999      | 3     | BCG-naive | Sasanlimab + BCG induction and maintenance Sasanlimab + BCG induction only BCG induction and maintenance | Event-free survival | December 2026 |

REFERENCES

1. International Agency for Research on Cancer. Bladder cancer fact sheet. Source: Globocan. 2020. [Cited 28 Apr 2021.] Available from URL: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf
2. International Agency for Research on Cancer. Estimated number of new cases from 2020 to 2040, both sexes, age [0–85+]: bladder. [Cited 30 Dec 2020.] Available from URL: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?cancers=30&single_unit=50000

REGISTRY AND THE REGISTRATION NO. OF THE STUDY/TRIAL

N/A.

ANIMAL STUDIES

N/A.
3 Antoni S, Ferlay J, Soerjomataram I, Azzou A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. *Eur. Urol.* 2017; 71: 96–108.
4 Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. *Eur. Urol.* 2008; 54: 303–14.
5 Chang SS, Boortjian SA, Chou R et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline 2016, amended. 2020 [Cited 28 Apr 2021.] Available from URL: https://www.auanet.org/guidelines/bladder-cancer-non-muscle-invasive-guideline
6 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer. Version 6.2020. Available from URL: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
7 Matsumoto K, Kikuchi E, Shirakawa H et al. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer. *BJU Int.* 2012; 110: E508–13.
8 Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. *Biomed. Pharmacother.* 2020; 129: 110393.
9 Chou R, Selph S, Buckley DI et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. *J. Urol.* 2017; 197: 1189–99.
10 Lerner SP, Dinney C, Kamat A et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. *Bladder Cancer* 2015; 1: 29–30.
11 Kamat AM, Flaig TW, Grossman HB et al. Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision. *Int. J. Urol.* 2020; 27: 702–9.
12 Kang LB, Kim JH, Lee JS, et al. Diagnosis and treatment of non-muscle invasive bladder cancer—current understanding and the prospect. *Korean J. Urol.* 2012; 53: 277–81.
13 Martinez-Pineiro L, Portillo JA, Fernandez JM. Intravesical bacillus Calmette-Guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive bladder cancer. *Urol. Oncol.* 2009; 27: 256–64.
14 Leibel SA, Kamat AM, Flaitz CM, et al. Lack of efficacy of bacillus Calmette-Guerin (BCG) for patients with advanced or recurrent non-muscle-invasive bladder cancer. *J. Urol.* 2012; 188: 321–9.
15 Lerner SP, Dinney C, Kamat A et al. Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. *Bladder Cancer* 2015; 1: 29–30.
16 Li R, Tabayoyong WB, Guo CC et al. Prognostic implication of the United States Food and Drug Administration-defined BCG-unresponsive disease. *Eur. Urol.* 2019; 75: 8–10.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

**Figure S1.** Schematic diagram of periods used to define the cohorts and outcomes.

**Figure S2.** Schematic diagram of the definitions of each cohort and subcohort.

**Figure S3.** Kaplan–Meier curve of time from first intravesical BCG prescription to next subsequent treatment for bladder cancer among patients with stage 0 or 1 disease (overall cohort).

**Figure S4.** Kaplan–Meier curve of time from first intravesical BCG prescription to cystectomy among patients with stage 0 or 1 disease (overall cohort).

**Figure S5.** Kaplan–Meier curve of time from first intravesical BCG administration to next subsequent treatment other than TURBT in (a) the overall cohort, and (b) the complete- and incomplete-induction cohorts.

**Figure S6.** Kaplan–Meier curve of time from first intravesical BCG prescription to next subsequent treatment for bladder cancer in the newly defined intensive (i.e. <9-day interval) and non-intensive (i.e. ≥9-day interval) BCG induction sub-cohort.

**Figure S7.** Kaplan–Meier curve of time from first intravesical BCG prescription to cystectomy in the newly defined intensive (i.e. <9-day interval) and non-intensive (i.e. ≥9-day interval) BCG induction sub-cohort.

**Table S1.** Definitions use to derive patient characteristics from the database entries.

**Table S2.** Definitions for bladder cancer treatments.

**Table S3.** Demographic and clinical characteristics of patients in the incomplete-induction cohort who did or did not experience an early event.

**Table S4.** Demographic and clinical characteristics of patients in the complete-induction cohort who received intensive versus non-intensive induction, based on a definition of intensive induction where the interval between consecutive BCG prescriptions was <9 days.